Recently, the Affiliated Cancer Hospital of ZZU has made new progress in Chimeric Antigen Receptor （CAR） T cells in the treatment of relapsed and refractory hematological neoplasms. The related research results were published in the international leading journal “Journal for ImmunoTherapy of Cancer” in the form of academic papers, with Dr. Han Lu as the first author.